Satraplatin as an Orally Active Pt(IV) Prodrug

Scientific poster examining Satraplatin's structure, mechanism, and clinical context as an orally active Pt(IV) prodrug.

Note: The extended report was not required for the assignment. We chose to produce it (with approval from the module supervisors) to strengthen the scientific rationale behind the poster and provide full references without overloading the layout.

At a glance

  • Outcome: Designed a scientific poster explaining Satraplatin’s structure, mechanism, and clinical context
  • Tools: ChemDraw (structures), BioRender (mechanism figure), AI‑generated title graphic
  • Skills: scientific communication, visual design, mechanism mapping, literature synthesis
  • Result highlight: clear, text‑light poster supported by a QR‑linked extended report

Overview

What makes Satraplatin a viable orally active Pt(IV) prodrug, and how does it differ mechanistically and clinically from cisplatin? Our group explored its design rationale, activation pathway, toxicity profile, and clinical prospects — then communicated this visually through a poster.

Objectives

  • Explain why Pt(IV) complexes enable oral delivery
  • Compare Satraplatin’s structure and behaviour to cisplatin
  • Illustrate the intracellular reduction pathway (Pt(IV) → Pt(II) JM‑118)
  • Summarise toxicity differences and clinical trial outcomes
  • Produce a clear, visually driven poster with minimal text
  • Provide deeper context via a QR‑linked extended report

Scope

Compounds included: Cisplatin · Satraplatin (JM‑216) · JM‑118 (active Pt(II) metabolite)

Approach

  • Reviewed literature on Pt(IV) prodrugs and Satraplatin’s development
  • Used ChemDraw to generate skeletal structures
  • Built a BioRender mechanism figure showing absorption, reduction, and DNA binding
  • Designed an AI‑assisted title graphic for visual identity
  • Structured the poster around minimal text + strong visuals
  • Added a QR code linking to a full written report for examiners

Results

1) Why Satraplatin works orally

  • Pt(IV) geometry provides stability in gastric acid
  • Axial acetato ligands increase lipophilicity → passive diffusion
  • Reduced intracellularly (glutathione/ascorbate) to JM‑118
  • Avoids premature hydrolysis, unlike cisplatin

Takeaway: Satraplatin’s design solves the “IV‑only” limitation of Pt(II) drugs.

2) Mechanism: how JM‑118 acts

  • Reduction converts Pt(IV) → Pt(II)
  • JM‑118 forms 1,2‑intrastrand guanine crosslinks
  • These adducts are poorly recognised by MMR and HMG proteins
  • Helps bypass cisplatin resistance pathways

3) Toxicity profile (vs cisplatin)

Feature Cisplatin Satraplatin
Nephrotoxicity High Low
Neurotoxicity Frequent Mild
Ototoxicity Moderate–severe Minimal
GI toxicity Severe Mild–moderate
Haematologic toxicity Mild Strong, dose‑limiting

Interpretation: Satraplatin trades renal/neuro toxicity for haematologic toxicity — a different but manageable profile.

Interpretation

What worked well

  • Clear mechanistic distinction from cisplatin
  • Strong visual communication using diagrams rather than dense text
  • Poster design aligned with best‑practice guidance (minimal text, strong figures)
  • QR code allowed deeper exploration without cluttering the layout

What was challenging

  • Balancing scientific depth with poster simplicity
  • Condensing complex Pt(IV) → Pt(II) chemistry into a single figure
  • Ensuring the mechanism diagram remained accurate while visually intuitive

Improvements

  • Include a small section on Pt(IV) reduction kinetics
  • Add a toxicity timeline or dose‑response visual
  • Provide a clearer comparison of clinical trial outcomes
  • Expand the QR‑linked report with more mechanistic detail

What I contributed

  • AI‑generated title artwork
  • ChemDraw structures for cisplatin and Satraplatin
  • BioRender mechanism figure (absorption → reduction → DNA binding)
  • Poster layout, colour palette, and visual hierarchy
  • Research and referencing, creating a shared Zotero reference manager for the project
  • Refinements of final poster content
  • Authored the extended report

What I learned

  • How to communicate complex mechanisms visually
  • How to design a poster that prioritises clarity over density
  • How to integrate AI‑assisted tools responsibly in scientific work
  • How to collaborate effectively on scientific communication